Ava, the Swiss-based medical technology company focused on women’s reproductive health, has raised $30 million in a strategic Series B funding round.
Ava’s cycle-tracking sensor bracelet precisely detects the 5.3-day fertile window in a woman’s cycle in real-time. According to Ava Co-founder, Pascal Koenig, the company will use the new funds for further product research and development to enhance the existing product and create new applications that empower women to take control of their reproductive health via data insights and science.
“Ava’s long-term vision is to accompany women through all stages of their reproductive life by providing data-driven, clinically proven technology that will make a woman’s life easier, healthier and better – be it when they just want to understand their body, while they are trying to prevent pregnancy, trying to get pregnant, are pregnant or entering menopause,” said Koenig.
Ava is continuously taking part in clinical trials with the University Hospital of Zurich under the direction of Prof Brigitte Leeners to study applications of the Ava technology among women trying to get pregnant, suffering from fertility challenges, and to understand complications during pregnancy.
Last year, Ava also hired its first Chief Medical Officer, Bayer Schering veteran Dr Maureen Cronin, to help shepherd the company through clinical and regulatory processes involved in new product development, particularly in the area of contraceptives.
“It’s exciting to work with a company that is literally reshaping the way we think about menstrual cycles, hormones and women’s health,” said Prof Leeners.
“Combining the best in science, data insights and technology is not only helping to create families, but improving women’s lives around the world,” concluded Prof Leeners.